Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Neoplasms × IMM-101 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 COVID-19 1

Interventions

fludarabine phosphate 2 fludarabine 2 Whole-Body Irradiation 2 Tacrolimus 2 Surveys and Questionnaires 2 Proton Therapy 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Cyclophosphamide 2 Busulfan 2 tremelimumab 1 motesanib diphosphate 1 luprolide acetate gel depot 1 liposomal amphotericin B 1 durvalumab 1 copanlisib 1 chlorhexidine gluconate 1 batifiban 1 Whole Genome Sequencing 1 Watchful Waiting 1 Thrombopoietin 1 Taxes 1 Spermine Synthase 1 Radiotherapy, Intensity-Modulated 1 Radiation 1 Psychiatrists 1 Psilocybin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04442048 2025-12-30

COV-IMMUNO

Canadian Cancer Trials Group

Phase 3 Completed

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡